The European Chemicals Agency (ECHA) has published a press release stating that '[it] is currently preparing an update of its Guidance on Information Requirements and Chemical Safety Assessment based on the output of the European Commission's REACH Implementation Projects on Nanomaterials [RIP-oNs]'.
RIP-oN2 and RIP-oN3 were conducted by a consortium consisting of SAFENANO (Institute of Occupational Medicine), the Nanotechnology Industries Association (NIA), the European Chemicals Industry Council (Cefic), and Soluzioni Informatiche, and ran from the beginning of 2010 until mid-2011.
ECHA's fast adoption of the RIP-oN recommendations is a 'ringing endorsement of the work, which we did in what were extremely challenging projects', highlights a SAFENANO spokesperson. Dr Steffi Friedrichs, Director General of the NIA, remembers: "Our diverse team of scientific experts both within the consortium and within the external expert advisory group had to conduct a thorough literature survey and gap analysis for each of the RIP-oNs and subsequently review several ECHA guidance documents with a view to making detailed recommendations for updates; each recommendation had to go through a transparent and fully documented commenting period with the European Commission and the appointed stakeholder consultation group, consisting of appointed Member States representatives and other experts". "The nanotechnology industries significantly supported the work through provision of 13 real-life exposure scenario case-studies, as well as expert opinion and insight", she adds.
According to ECHA's press release, '[t]he final reports of the two projects gained broad support from the different stakeholders participating in the project and were subsequently transmitted by the Commission to ECHA...ECHA will incorporate the specific advice into its guidance to enable appropriate safety assessment.it will facilitate compliance of all potential registrants well in advance of the next REACH registration deadline (31 May 2013). Registrants may already now find it useful to refer to the RIP-oN 2 & 3 reports when preparing registration dossiers covering nanomaterials. However, registrants are reminded to ensure that safe use of their substance should be demonstrated in the registration dossier, and hence that the data of the submitted properties as well as related risk assessment and management information should be applicable and appropriate for the nanoforms covered by the registration'.